Biotech Market Intelligence & Analysis
In-depth articles on the biotech landscape — market analysis, sector reports, funding trends, and company spotlights.
Biotech IPOs: Complete Guide to Going Public
For biotechnology companies, the decision to go public is rarely a simple matter of ambition. It is a critical, capital-intensive milestone on the path from scientific discovery to commercial therapy. The biotech model is fundamentally built on a cycle of high-risk, high-reward r
Digital Health and Diagnostics Companies Leading Innovation
The healthcare landscape is undergoing a fundamental transformation, driven by the convergence of advanced diagnostics, data science, and digital connectivity. The rigid boundary between the physical and digital worlds in medicine is dissolving, giving rise to a new paradigm of p
Orphan Drugs and Rare Disease Biotech Companies
In the calculus of modern drug development, where blockbuster ambitions often target millions of patients, a counterintuitive model has emerged as one of biotech's most lucrative: targeting the few. The rare disease sector, once a neglected backwater of pharmaceutical research, h
Biotech Market Cap: From $1T to $7.5T — A 35-Year History
From a nascent collection of research-driven startups to a foundational pillar of global healthcare and a multi-trillion-dollar economic engine, the biotechnology industry has undergone a transformation unparalleled in modern business history. The journey from a roughly $100 bill
Gene Therapy Companies: A Complete Landscape Guide
The fundamental premise of gene therapy—to treat or cure disease by correcting, replacing, or modulating defective genes—has evolved from a scientific aspiration into a commercial and clinical reality. After decades of setbacks and incremental progress, the field has entered a ne
Immunotherapy Companies: The Race Against Cancer
For decades, the oncology armamentarium rested on three pillars: surgery, radiation, and chemotherapy. While effective, these approaches often came with significant collateral damage, targeting rapidly dividing cells indiscriminately. The dawn of the 21st century ushered in a tra
Small Molecule Drugs: The Backbone of Pharma
In an era dominated by headlines about gene therapies, monoclonal antibodies, and cell-based treatments, a quieter, more persistent force continues to drive the global pharmaceutical industry: small molecule drugs. Defined as chemically synthesized, low-molecular-weight compounds
Japanese Biotech Market: Companies to Watch
Japan stands as a formidable and distinctive pillar in the global biotechnology landscape. It is a market defined by a deep-rooted pharmaceutical heritage, world-class scientific innovation, and a regulatory system that has evolved to champion cutting-edge therapies. While often
The Rise of European Biotech: Market Overview
For decades, the narrative of biotechnology innovation has been dominated by the United States, with its deep venture capital pools and concentrated hubs like Boston and San Francisco. However, a quiet revolution has been building across the Atlantic. European biotech is no longe
Biotech Funding in 2026: Where VCs Are Investing
As we reach the midpoint of 2026, the biotech venture funding landscape is defined by a powerful dichotomy: immense pools of capital are available, but their deployment is more disciplined and concentrated than ever before. The era of "spray and pray" investing is firmly in the r
AI in Drug Discovery: The Companies Transforming Pharma
The pharmaceutical industry is in the midst of a profound transformation, driven not by a new class of molecules, but by a new class of tools: artificial intelligence and machine learning. The traditional drug discovery process is notoriously inefficient, often described as findi
mRNA Technology: Companies Pushing the Boundaries Beyond COVID
The rapid development and deployment of mRNA-based COVID-19 vaccines was a watershed moment for medicine, validating a platform that had been in development for decades. The success of Pfizer-BioNTech's Comirnaty and Moderna's Spikevax proved that synthetic mRNA could be safely a